Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 87 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-a agents. Drug Saf 2016;39:199-208. [Ref.ID 100140]
3. Cita con resumen
Simon PC, Vallano A. Fármacos que inhiben el factor de necrosis tumoral alfa y embarazo. Med Clin (Barc) 2013;141:257-9. [Ref.ID 96078]
4. Cita con resumen
Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [Ref.ID 96072]
5.Tiene citas relacionadas
Dixon W, Felson DT. Is anti-TNF therapy safer than previously throught?. JAMA 2011;306:2331. [Ref.ID 91687]
6.Tiene citas relacionadas Cita con resumen
Grijalva CG, Chen L, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-alfa antagonists and the risk of hospitalization for infection in patients with autoimmune diseses. JAMA 2011;306:2331-9. [Ref.ID 91686]
7. Cita con resumen
Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ. Infecciones en pacientes tratados con antagonistas del factor de necrosis tumoral: incidencia, etiología y mortalidad en el registro BIOBADASER. Med Clin (Barc) 2011;137:533-40. [Ref.ID 91581]
8. Cita con resumen
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57. [Ref.ID 88168]
11.
Anónimo. Certolizumab (Cimzia) for Crohn's disease. Med Lett Drugs Ther 2008;50:81-2. [Ref.ID 84441]
12.
Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81. [Ref.ID 83496]
13. Cita con resumen
Tanne JH. Drugs for rheumatoid arthritis may have heart benefits. BMJ 2008;336:580. [Ref.ID 82377]
14. Cita con resumen
Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008;358:843-9. [Ref.ID 82210]
15.Tiene citas relacionadas Cita con resumen
List AF. Lenalidomide - The phoenix rises. N Engl J Med 2007;357:2183-6. [Ref.ID 81605]
16.Tiene citas relacionadas
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, for the Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42. [Ref.ID 81602]
17.Tiene citas relacionadas
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San MIguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnychyj M, Yu Z, Patrin J, Zeldis JB, Knight RD, for the Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32. [Ref.ID 81601]
18.Tiene citas relacionadas
Lewis JD. Anti-TNF antibodies for Crohn's disease. The editorialist replies. N Engl J Med 2007;357:1662. [Ref.ID 81311]
19.Tiene citas relacionadas
Camilleri M. Anti-TNF antibodies for Crohn's disease. N Engl J Med 2007;357:1662. [Ref.ID 81310]
20.
Emery P, Kvien TK. Treating rheumatoid arthritis. BMJ 2007;335:56-7. [Ref.ID 80714]
Seleccionar todas
 
 1 a 20 de 87 siguiente >>